Entacapone Prolongs the Reduction of PLM by Levodopa/Carbidopa in Restless Legs Syndrome
| Autor: | Juha Ellmen, Johanna Karvinen, Mikko Vahteristo, Olli Polo, Kari Hirvonen, Riitta Ylä-Sahra |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
medicine.medical_specialty
Levodopa Movement Polysomnography Catechols Decarboxylase inhibitor Placebo Severity of Illness Index Double-Blind Method Restless Legs Syndrome Nitriles medicine Humans Pharmacology (medical) Entacapone Prospective Studies Restless legs syndrome Enzyme Inhibitors Pharmacology Cross-Over Studies Dose-Response Relationship Drug medicine.diagnostic_test business.industry Carbidopa medicine.disease Crossover study Surgery Drug Combinations Delayed-Action Preparations Anesthesia Drug Therapy Combination Neurology (clinical) business medicine.drug |
| Zdroj: | Clinical Neuropharmacology. 30:335-344 |
| ISSN: | 0362-5664 |
| DOI: | 10.1097/wnf.0b013e31805930c2 |
| Popis: | Objectives: Levodopa is effective in the treatment of restless legs syndrome (RLS). However, due to the short duration of action of conventional levodopa/ decarboxylase inhibitor formulations, multiple dosing may be required in individual patients with persisting symptoms. We assessed whether a new levodopa formulation containing levodopa, carbidopa, and entacapone (LCE) improves levodopa action in RLS. Methods: Twenty-eight RLS patients with periodic limb movement (PLM) received single doses of Stalevo 50 (LCE50; 50/12.5/200 mg), Stalevo 100 (LCE100; 100/25/200 mg), Stalevo 150 (LCE150; 150/37.5/ 200 mg), Sinemet 100 (LC100; 100/25 mg), or placebo in a randomized, double-blind, crossover study with polysomnography. Periodic limb movements per hour (PLM/h) during total sleep time and PLM during total time in bed were the primary and secondary variables, respectively. Results: Mean PLM/h during total sleep time after Stalevo 50 (12.6/h, P < 0.05), LCE100, LCE150, and LC100 (6.4/h, 3.5/h and 9.5/h, respectively; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|